



STATE OF WEST VIRGINIA
DEPARTMENT OF HUMAN SERVICES
BUREAU FOR MEDICAL SERVICES

Carl Ayers, MSW
Cabinet Secretary

Christy D. Donohue, CMC
Commissioner

Pharmaceutical and Therapeutics Committee

August 26th, 2026

Location: Webex only
Time: Executive Session 2:00 PM - 3:00 PM
Time: Open Session 3:00 PM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

AGENDA

- I. Executive Session- 2:00PM-3:00PM
- II. Call to Order – Call in information for the 3:00 PM Open Session is
+1 952-222-7450 meeting code 984990258#
Join: [Join Teams Meeting](#)
Meeting ID: 261 688 046 908 830
Passcode: Bh32TB7X
- III. Welcome and Introductions
- IV. Housekeeping Items/Updates
 - a. Approval of the January 28th, 2026, Minutes
 - b. PDL Compliance/Generic Percent Report Updates
- V. Public Comments (Agenda classes only) – Public comments for this meeting will only be accepted in writing. Comments need to be sent via email to Kristen Boustany (kristen.n.boustany@wv.gov) no later than August 12th, 2026. Comments will be forwarded to committee members prior to the meeting for their review and consideration.

Representatives of drug manufacturers being presented at P&T can register to be on hand to answer any questions put forth by P&T committee members. Registrants must provide a name, email address, name of drug and company they are representing, and provide a completed [disclosure form](#) to the email address above no later than August 12th, 2026.



VI. New Business

a. New Drug Overviews

- i. Antiemetics
 1. NEREUS (tradipitant)
- ii. Antihypertensives, Miscellaneous
 1. BAXFENDY (baxdrostat)
 2. TRYVIO (aprocitentan)
- iii. Antipsychotics, Atypical and Combination
 1. BYSANTI (milsaperidone)
- iv. Antiretrovirals
 1. IDVYNZO (doravirine/islatravir)
- v. Calcium Channel Blockers
 1. CARDAMYST (etripamil)
 2. SDAMLO (amlodipine powder for solution)
- vi. Cytokine and CAM Antagonists
 1. AVTOZMA (tocilizumab-anoh)
 2. ICOTYDE (icotrokinra)
 3. STARJEMZA (ustekinumab-hmny)
 4. USTEKINUMAB-AAUZ
 5. USTEKINUMAB-TTWE
 6. USTEKINUMAB-AEKN
- vii. Diabetes Agents, GLP1-Agonist
 1. OZEMPIC TABLETS (semaglutide)
- viii. Growth Hormones and Achondroplasia Agents
 1. VOXZOGO (vosoritide)
 2. YUVIWEL (navepegritide)
- ix. Hepatitis D Agents ***NEW CLASS**
 1. HEPCLUDEX (bulevirtide-gmod)
- x. Hereditary Angioedema Agents
 1. ORLADEYO ORAL PELLETS (berotralstat)
- xi. Lipotropics, Other
 1. REDEMPLO (plozasiran)
- xii. Neuropathic Pain
 1. RELGAABI (gabapentin)
- xiii. NSAID
 1. ORUDIS (ketoprofen)
 2. ZYBIC (meloxicam suspension)
- xiv. Opiate Dependence Treatments
 1. REZENOPY (naloxone nasal spray)
- xv. Ophthalmics, Anti-Inflammatories
 1. BYQLOVI (clobetasol propionate ophthalmic suspension)
- xvi. Ophthalmics, Glaucoma Agents
 1. ZOLYMBUS (bimatoprost ophthalmic gel)
- xvii. Skeletal Muscle Relaxants
 1. ATMEKSI (methocarbamol oral suspension)
 2. ONTRALFY (tizanidine solution)



Letter Name

Date

Page 3

- xviii. Stimulants and Related Agents
 - 1. ARYNTA (lisdexamfetamine solution)

- b. Drug Class Reviews
 - i. None

VII. Old Business

VIII. Other Business

IX. Next Meeting –November 4th, 2026, Annual P&T Meeting (IN PERSON)
Meeting will begin at 9:00 AM and is scheduled until 5:00PM EST.

Address:

Saint John XXIII Pastoral Center
100 Hodges Rd
Charleston, WV 25314

X. Adjournment

